Bio-Rad (BIO) to Commercialize Genetic Analysis's GA-map Technology for the Detection of Gut Dysbiosis

November 28, 2016 4:18 PM EST

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed an agreement in which Genetic Analysis will receive an equity investment from Bio-Rad (NYSE: BIO) in exchange for commercialization rights, in certain territories, for Genetic Analysis’s GA-map™ technology to detect gut dysbiosis. Terms of the agreement were not disclosed.

The patented GA-map™ technology is used as an aide in the diagnosis and management of irritable bowel syndrome and inflammatory bowel disease.

Dysbiosis is a microbial imbalance or maladaptation on or inside the body and is most commonly reported as a condition in the digestive tract. It has been associated with illnesses, such as inflammatory bowel disease and other chronic diseases.

“We are delighted to be linking up with Bio-Rad, a major force for innovation in in vitro diagnostic testing,” said Ronny Hermansen, CEO of Genetic Analysis. “We believe that this collaboration will accelerate the penetration of the GA tests into routine healthcare as the importance of the microbiome in major diseases becomes increasingly recognised.”

“We welcome the opportunity to partner with Genetic Analysis,” said Norman Schwartz, Bio-Rad President and CEO. “With the GA-map technology, we can offer products to analyze the microbiome associated with gut dysbiosis, which affects the quality of life of many patients around the world and can result in serious health problems.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment